MA44008A - 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b - Google Patents
1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2bInfo
- Publication number
- MA44008A MA44008A MA044008A MA44008A MA44008A MA 44008 A MA44008 A MA 44008A MA 044008 A MA044008 A MA 044008A MA 44008 A MA44008 A MA 44008A MA 44008 A MA44008 A MA 44008A
- Authority
- MA
- Morocco
- Prior art keywords
- nr2b
- substituted
- selective nmda
- nmda modulators
- triazoles used
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293680P | 2016-02-10 | 2016-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44008A true MA44008A (fr) | 2018-12-19 |
Family
ID=58054551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044008A MA44008A (fr) | 2016-02-10 | 2017-02-09 | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10071988B2 (fr) |
| EP (1) | EP3414233A1 (fr) |
| JP (1) | JP6923543B2 (fr) |
| KR (1) | KR20180108822A (fr) |
| CN (1) | CN109071488B (fr) |
| AU (1) | AU2017217542B2 (fr) |
| BR (1) | BR112018016329A2 (fr) |
| CA (1) | CA3014314A1 (fr) |
| EA (1) | EA201891799A1 (fr) |
| IL (1) | IL261046B (fr) |
| MA (1) | MA44008A (fr) |
| MX (1) | MX2018009752A (fr) |
| SG (1) | SG11201806750WA (fr) |
| WO (1) | WO2017139428A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016025917A1 (fr) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles à titre d'inhibiteurs des récepteurs nr2b |
| US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| US10071988B2 (en) | 2016-02-10 | 2018-09-11 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2019193516A2 (fr) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| EP3818045A1 (fr) | 2018-07-03 | 2021-05-12 | Helmholtz-Zentrum für Infektionsforschung GmbH | Agonistes inverses de pqsr |
| CA3143103A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Carbamates de pyridine et leur utilisation en tant que modulateurs du recepteur glun2b |
| CN114008052A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| BR112021025141A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b |
| MX2021015511A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de pirazina y sus usos como moduladores del receptor glun2b. |
| TW202112774A (zh) | 2019-06-14 | 2021-04-01 | 比利時商健生藥品公司 | 經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途 |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
| WO2021253180A1 (fr) * | 2020-06-15 | 2021-12-23 | Novartis Ag | Méthyl(r)-2-(fluorométhyl)-5-oxo-4-phényl-4,5,6, 7-tétrahydro-1h-cyclopenta[b]pyridine-3-carboxylate et méthyl(r)-2-(fluorométhyl)-5-oxo-4-phényl-1,4,5,7-tétrahydrofuro[3,4-b]pyridine-3-carboxylate utilisés en tant qu'activateurs de cav1.2 |
| WO2024077292A2 (fr) * | 2022-10-07 | 2024-04-11 | Augusta University Research Institute, Inc. | Synthèse de conjugués d'ains utilisés en tant qu'agents anti-inflammatoires et analgésiques à l'aide de l'approche d'hybridation moléculaire |
| CN115947692B (zh) * | 2022-12-28 | 2024-12-27 | 上海再启生物技术有限公司 | 一种制备2-氯-4-(甲氧基甲基)嘧啶的方法 |
| WO2024208292A1 (fr) * | 2023-04-04 | 2024-10-10 | 江苏亚虹医药科技股份有限公司 | Inhibiteur de protéase 1 spécifique de l'ubiquitine, son procédé de préparation et son utilisation médicale |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| DE60316542T2 (de) | 2002-03-28 | 2008-07-03 | Eisai R&D Management Co., Ltd. | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| DE10315570A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Triazolderivate |
| RU2006127575A (ru) * | 2004-02-18 | 2008-03-27 | Астразенека Аб (Se) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| JP5266042B2 (ja) * | 2005-04-11 | 2013-08-21 | エール ユニヴァーシティ | 統合失調症前駆症の治療方法 |
| WO2007115231A2 (fr) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Modulateurs de cxcr4 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| EP2167464B1 (fr) | 2007-05-25 | 2014-12-03 | AbbVie Deutschland GmbH & Co KG | Composés hétérocycliques comme modulateurs positifs du récepteur métabotropique du glutamate 2 (récepteur mglu2) |
| JPWO2009028543A1 (ja) | 2007-08-30 | 2010-12-02 | 武田薬品工業株式会社 | 置換ピラゾール誘導体 |
| EP2215073A4 (fr) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | Modulation du sommeil avec des antagonistes du récepteur nr2b |
| MX2010009649A (es) * | 2008-03-27 | 2010-12-17 | Evotecv Neurosciences Gmbh | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
| BRPI0917540A2 (pt) | 2008-08-05 | 2015-11-17 | Daiichi Sankyo Co Ltd | composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| WO2010043396A1 (fr) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Dérivés d’indole et de benzomorpholine en tant que modulateurs des récepteurs métabotropiques du glutamate |
| WO2010068483A2 (fr) | 2008-11-25 | 2010-06-17 | University Of Rochester | Inhibiteurs de mlk et procédés d'utilisation |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| EP2579717A4 (fr) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | Modulateurs allostériques positifs de mglur2 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| WO2013130855A1 (fr) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Dérivés d'indazole |
| WO2014124651A1 (fr) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur |
| EP2970200A1 (fr) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Inhibiteurs de pyridine cdk9 kinase |
| US10155727B2 (en) | 2014-08-15 | 2018-12-18 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| WO2016025917A1 (fr) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles à titre d'inhibiteurs des récepteurs nr2b |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| US10071988B2 (en) | 2016-02-10 | 2018-09-11 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| WO2019193516A2 (fr) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
-
2017
- 2017-02-09 US US15/428,710 patent/US10071988B2/en active Active
- 2017-02-09 WO PCT/US2017/017093 patent/WO2017139428A1/fr not_active Ceased
- 2017-02-09 KR KR1020187026142A patent/KR20180108822A/ko not_active Withdrawn
- 2017-02-09 EA EA201891799A patent/EA201891799A1/ru unknown
- 2017-02-09 JP JP2018541636A patent/JP6923543B2/ja not_active Expired - Fee Related
- 2017-02-09 AU AU2017217542A patent/AU2017217542B2/en not_active Ceased
- 2017-02-09 CA CA3014314A patent/CA3014314A1/fr active Pending
- 2017-02-09 MA MA044008A patent/MA44008A/fr unknown
- 2017-02-09 BR BR112018016329A patent/BR112018016329A2/pt not_active Application Discontinuation
- 2017-02-09 CN CN201780022887.6A patent/CN109071488B/zh not_active Expired - Fee Related
- 2017-02-09 EP EP17705768.4A patent/EP3414233A1/fr not_active Withdrawn
- 2017-02-09 MX MX2018009752A patent/MX2018009752A/es unknown
- 2017-02-09 SG SG11201806750WA patent/SG11201806750WA/en unknown
-
2018
- 2018-07-26 US US16/046,332 patent/US10233173B2/en active Active
- 2018-08-08 IL IL261046A patent/IL261046B/en unknown
- 2018-12-31 US US16/237,333 patent/US10766880B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017217542B2 (en) | 2021-06-03 |
| MX2018009752A (es) | 2019-02-07 |
| US20170226089A1 (en) | 2017-08-10 |
| CN109071488B (zh) | 2021-08-13 |
| BR112018016329A2 (pt) | 2018-12-18 |
| AU2017217542A1 (en) | 2018-08-23 |
| JP2019504854A (ja) | 2019-02-21 |
| US20180334451A1 (en) | 2018-11-22 |
| US20190135791A1 (en) | 2019-05-09 |
| EA201891799A1 (ru) | 2019-02-28 |
| SG11201806750WA (en) | 2018-09-27 |
| US10071988B2 (en) | 2018-09-11 |
| WO2017139428A1 (fr) | 2017-08-17 |
| JP6923543B2 (ja) | 2021-08-18 |
| IL261046B (en) | 2021-09-30 |
| US10233173B2 (en) | 2019-03-19 |
| CA3014314A1 (fr) | 2017-08-17 |
| IL261046A (en) | 2019-02-28 |
| KR20180108822A (ko) | 2018-10-04 |
| US10766880B2 (en) | 2020-09-08 |
| EP3414233A1 (fr) | 2018-12-19 |
| CN109071488A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44008A (fr) | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b | |
| FR24C1009I2 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| CY1123853T1 (el) | Ρυθμιστες nrf2 | |
| MA52157A (fr) | Dinucléotides cycliques de purine utilisés comme modulateurs de sting | |
| EP3408268B8 (fr) | Derives de benzimidazole comme des modulateurs de ror-gamma | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| MX389001B (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| EP3727401A4 (fr) | Composés dinucléotidiques cycliques utilisés comme agonistes sting | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| MA46373A (fr) | Composés utilisés comme modulateurs de ror gamma | |
| MA49357A (fr) | Composés, compositions et méthodes permettant de moduler le cftr | |
| WO2015191951A3 (fr) | Modulation d'activité du complément | |
| DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
| EP3681499A4 (fr) | Composés utilisés comme inhibiteurs de ras et leur utilisation | |
| EP3622034A4 (fr) | Composition(s) de revêtement | |
| HUE052833T2 (hu) | Eljárás 2,5-furándikarbonsav (FDCA) elõállítására | |
| EP3386952A4 (fr) | Composés de benzimidazolium, pyrido-imidazolium ou pyrazino-imidazolium substitués utilisés comme agents chimiothérapeutiques | |
| EP3552017A4 (fr) | Composés, compositions et méthodes | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| EA201792262A1 (ru) | Пироглутамат вортиоксетина | |
| UA117779C2 (uk) | Піразини як модулятори gpr6 | |
| AU2016361427A8 (en) | Platinum anticancer agents | |
| EP3368539A4 (fr) | Composés indazole substitués utilisés en tant qu'inhibiteurs de rorgammat et utilisations associées | |
| WO2014152809A3 (fr) | Analogues de pparo et de 20-oh-pge2, et procédés d'utilisation de ceux-ci | |
| WO2016109361A3 (fr) | Inhibiteurs 3-fluoro-benzonitriles de la 11-bêta-hydroxylase |